Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors

L. Ferrari, E. Seregni, G. Lucignani, E. Bajetta, A. Martinetti, G. Aliberti, F. Pallotti, G. Procopio, S. Della Torre, R. Luksch, Emilio Bombardieri

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Measurement of chromogranin A (CgA) plays a major role in the management of neuroendocrine tumors (NET); however, reliable assaying of CgA is made difficult by the rapid hydrolysis following its release into the bloodstream. This study was aimed at the assessment of two assays for CgA in NET patients. CgA was measured in 93 patients by means of an enzyme-linked immunosorbent assay (ELISA) and an immunoradiometric assay (IRMA). The specificity and sensitivity of CgA were evaluated in relation to tumor histology. The clinical accuracy of the two assays was evaluated by receiver-operating characteristic (ROC) curve analysis. Regression analysis demonstrated different immunoreactivity for CgA of the antibodies used in the two kits (r=0.61). The two assays had different accuracy also in classifying patients according to their clinical condition (91% vs 64% specificity and 79% vs 79% sensitivity for the ELISA and IRMA assay, respectively) and tumor histology (81% vs 85% sensitivity for the ELISA and IRMA assays, respectively, in carcinoids; 92% vs 67% sensitivity for the ELISA and IRMA assays, respectively, in pancreatic islet cell tumors). The different clinical accuracy of the two assays was confirmed by the ROC analysis (AUC=0.90 vs AUC=0.87 for the ELISA and IRMA assays, respectively). In conclusion, because of the poor standardization of the commercially available measurement tools the clinical accuracy of CgA measurement depends on the assay used. This makes it difficult to compare CgA values measured with different kits and affects the clinical accuracy of the different assays for CgA.

Original languageEnglish
Pages (from-to)295-304
Number of pages10
JournalInternational Journal of Biological Markers
Volume19
Issue number4
Publication statusPublished - Oct 2004

Fingerprint

Chromogranin A
Neuroendocrine Tumors
Tumors
Assays
Immunoradiometric Assay
Enzyme-Linked Immunosorbent Assay
Immunosorbents
ROC Curve
Area Under Curve
Histology
Enzymes
Carcinoid Tumor
Neoplasms
Hydrolysis
Regression Analysis
Sensitivity and Specificity
Antibodies

Keywords

  • Carcinoid
  • Chromogranin A
  • Enzyme-linked immunosorbent assay
  • Immunoradiometric assay
  • Neuroendocrine tumors
  • Pancreatic islet cell tumor
  • Tumor markers

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. / Ferrari, L.; Seregni, E.; Lucignani, G.; Bajetta, E.; Martinetti, A.; Aliberti, G.; Pallotti, F.; Procopio, G.; Della Torre, S.; Luksch, R.; Bombardieri, Emilio.

In: International Journal of Biological Markers, Vol. 19, No. 4, 10.2004, p. 295-304.

Research output: Contribution to journalArticle

Ferrari, L, Seregni, E, Lucignani, G, Bajetta, E, Martinetti, A, Aliberti, G, Pallotti, F, Procopio, G, Della Torre, S, Luksch, R & Bombardieri, E 2004, 'Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors', International Journal of Biological Markers, vol. 19, no. 4, pp. 295-304.
Ferrari, L. ; Seregni, E. ; Lucignani, G. ; Bajetta, E. ; Martinetti, A. ; Aliberti, G. ; Pallotti, F. ; Procopio, G. ; Della Torre, S. ; Luksch, R. ; Bombardieri, Emilio. / Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. In: International Journal of Biological Markers. 2004 ; Vol. 19, No. 4. pp. 295-304.
@article{841a1dee8a5e483e9665bed44086763e,
title = "Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors",
abstract = "Measurement of chromogranin A (CgA) plays a major role in the management of neuroendocrine tumors (NET); however, reliable assaying of CgA is made difficult by the rapid hydrolysis following its release into the bloodstream. This study was aimed at the assessment of two assays for CgA in NET patients. CgA was measured in 93 patients by means of an enzyme-linked immunosorbent assay (ELISA) and an immunoradiometric assay (IRMA). The specificity and sensitivity of CgA were evaluated in relation to tumor histology. The clinical accuracy of the two assays was evaluated by receiver-operating characteristic (ROC) curve analysis. Regression analysis demonstrated different immunoreactivity for CgA of the antibodies used in the two kits (r=0.61). The two assays had different accuracy also in classifying patients according to their clinical condition (91{\%} vs 64{\%} specificity and 79{\%} vs 79{\%} sensitivity for the ELISA and IRMA assay, respectively) and tumor histology (81{\%} vs 85{\%} sensitivity for the ELISA and IRMA assays, respectively, in carcinoids; 92{\%} vs 67{\%} sensitivity for the ELISA and IRMA assays, respectively, in pancreatic islet cell tumors). The different clinical accuracy of the two assays was confirmed by the ROC analysis (AUC=0.90 vs AUC=0.87 for the ELISA and IRMA assays, respectively). In conclusion, because of the poor standardization of the commercially available measurement tools the clinical accuracy of CgA measurement depends on the assay used. This makes it difficult to compare CgA values measured with different kits and affects the clinical accuracy of the different assays for CgA.",
keywords = "Carcinoid, Chromogranin A, Enzyme-linked immunosorbent assay, Immunoradiometric assay, Neuroendocrine tumors, Pancreatic islet cell tumor, Tumor markers",
author = "L. Ferrari and E. Seregni and G. Lucignani and E. Bajetta and A. Martinetti and G. Aliberti and F. Pallotti and G. Procopio and {Della Torre}, S. and R. Luksch and Emilio Bombardieri",
year = "2004",
month = "10",
language = "English",
volume = "19",
pages = "295--304",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "4",

}

TY - JOUR

T1 - Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors

AU - Ferrari, L.

AU - Seregni, E.

AU - Lucignani, G.

AU - Bajetta, E.

AU - Martinetti, A.

AU - Aliberti, G.

AU - Pallotti, F.

AU - Procopio, G.

AU - Della Torre, S.

AU - Luksch, R.

AU - Bombardieri, Emilio

PY - 2004/10

Y1 - 2004/10

N2 - Measurement of chromogranin A (CgA) plays a major role in the management of neuroendocrine tumors (NET); however, reliable assaying of CgA is made difficult by the rapid hydrolysis following its release into the bloodstream. This study was aimed at the assessment of two assays for CgA in NET patients. CgA was measured in 93 patients by means of an enzyme-linked immunosorbent assay (ELISA) and an immunoradiometric assay (IRMA). The specificity and sensitivity of CgA were evaluated in relation to tumor histology. The clinical accuracy of the two assays was evaluated by receiver-operating characteristic (ROC) curve analysis. Regression analysis demonstrated different immunoreactivity for CgA of the antibodies used in the two kits (r=0.61). The two assays had different accuracy also in classifying patients according to their clinical condition (91% vs 64% specificity and 79% vs 79% sensitivity for the ELISA and IRMA assay, respectively) and tumor histology (81% vs 85% sensitivity for the ELISA and IRMA assays, respectively, in carcinoids; 92% vs 67% sensitivity for the ELISA and IRMA assays, respectively, in pancreatic islet cell tumors). The different clinical accuracy of the two assays was confirmed by the ROC analysis (AUC=0.90 vs AUC=0.87 for the ELISA and IRMA assays, respectively). In conclusion, because of the poor standardization of the commercially available measurement tools the clinical accuracy of CgA measurement depends on the assay used. This makes it difficult to compare CgA values measured with different kits and affects the clinical accuracy of the different assays for CgA.

AB - Measurement of chromogranin A (CgA) plays a major role in the management of neuroendocrine tumors (NET); however, reliable assaying of CgA is made difficult by the rapid hydrolysis following its release into the bloodstream. This study was aimed at the assessment of two assays for CgA in NET patients. CgA was measured in 93 patients by means of an enzyme-linked immunosorbent assay (ELISA) and an immunoradiometric assay (IRMA). The specificity and sensitivity of CgA were evaluated in relation to tumor histology. The clinical accuracy of the two assays was evaluated by receiver-operating characteristic (ROC) curve analysis. Regression analysis demonstrated different immunoreactivity for CgA of the antibodies used in the two kits (r=0.61). The two assays had different accuracy also in classifying patients according to their clinical condition (91% vs 64% specificity and 79% vs 79% sensitivity for the ELISA and IRMA assay, respectively) and tumor histology (81% vs 85% sensitivity for the ELISA and IRMA assays, respectively, in carcinoids; 92% vs 67% sensitivity for the ELISA and IRMA assays, respectively, in pancreatic islet cell tumors). The different clinical accuracy of the two assays was confirmed by the ROC analysis (AUC=0.90 vs AUC=0.87 for the ELISA and IRMA assays, respectively). In conclusion, because of the poor standardization of the commercially available measurement tools the clinical accuracy of CgA measurement depends on the assay used. This makes it difficult to compare CgA values measured with different kits and affects the clinical accuracy of the different assays for CgA.

KW - Carcinoid

KW - Chromogranin A

KW - Enzyme-linked immunosorbent assay

KW - Immunoradiometric assay

KW - Neuroendocrine tumors

KW - Pancreatic islet cell tumor

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=19944429557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944429557&partnerID=8YFLogxK

M3 - Article

C2 - 15646836

AN - SCOPUS:19944429557

VL - 19

SP - 295

EP - 304

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 4

ER -